<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="and development. Importantly, WIPO Re:Search also drives progress toward the" exact="United Nations" post="Sustainable Development Goals (SDGs). Through case studies, we illustrate"/>
 <result pre="new cases and 435,000 deaths in 2017, predominantly in the" exact="World Health Organization" post="(WHO) African Region. No significant reduction in malaria cases"/>
 <result pre="or eliminate them, are evidenced by their inclusion in the" exact="United Nations" post="(UN) Sustainable Development Goals (SDGs). SDG Target 3.3 aims"/>
 <result pre="for lymphatic filariasis and onchocerciasis from MSD (a trademark of" exact="Merck" post="&amp;amp; Co., Inc., Kenilworth, NJ, USA), praziquantel (PZQ) for"/>
 <result pre="Co., Inc., Kenilworth, NJ, USA), praziquantel (PZQ) for schistosomiasis from" exact="Merck" post="KGaA, and Zithromax® (azithromycin) for trachoma from Pfizer. Partnerships"/>
 <result pre="(PDPs) such as Drugs for Neglected Diseases initiative (DNDi) and" exact="Medicines for Malaria Venture" post="(MMV). WIPO Re:Search also stimulates drug R&amp;amp;D focused on"/>
 <result pre="eight pharmaceutical companies (Eisai Co., Ltd.; GlaxoSmithKline; Johnson &amp;amp; Johnson;" exact="Merck" post="KGaA; MSD; Novartis; Pfizer; and Takeda Pharmaceutical Company, Ltd.);"/>
 <result pre="GlaxoSmithKline; Johnson &amp;amp; Johnson; Merck KGaA; MSD; Novartis; Pfizer; and" exact="Takeda Pharmaceutical Company," post="Ltd.); eight PDPs (DNDi; FIND; GALVmed; International Vaccine Institute;"/>
 <result pre="eight PDPs (DNDi; FIND; GALVmed; International Vaccine Institute; MMV; PATH;" exact="Sabin Vaccine Institute;" post="and Texas Children’s Hospital Center for Vaccine Development); and"/>
 <result pre="to further advance the work. A funding opportunity from the" exact="Wellcome Trust," post="aimed at stimulating partnerships between for-profit and non-profit entities,"/>
 <result pre="PAR1 inhibitors, Professor Craig contacted BVGH, which connected him with" exact="Eisai" post="Co., Ltd. through WIPO Re:Search. Seeking new opportunities to"/>
 <result pre="fight tropical diseases and potentially benefit millions of people worldwide," exact="Eisai" post="shared its PAR1 inhibitors (originally developed to treat coronary"/>
 <result pre="barrier function, Professor Craig was awarded a US$53,000 United Kingdom" exact="Medical Research Council" post="Confidence in Concept grant to test additional Eisai PAR1"/>
 <result pre="Medical Research Council Confidence in Concept grant to test additional" exact="Eisai" post="PAR1 inhibitors using more complex models [31]. 3.2. Schistosomiasis"/>
 <result pre="pathways that are not altered by PZQ. While at the" exact="University of California," post="San Francisco, Dr. Conor Caffrey validated Schistosoma 3-hydroxy-3-methylglutaryl coenzyme"/>
 <result pre="hypercholesterolemia, have schistosomicidal activity [32]. Dr. Caffrey, now at the" exact="University of California," post="San Diego, subsequently launched a drug discovery program with"/>
 <result pre="project have been facilitated with competitively awarded funds from the" exact="National Institutes of Health" post="[33]. 3.3. Dengue The global burden of dengue has"/>
 <result pre="fever. Modipafant was under development by Pfizer, but was discontinued." exact="Pfizer" post="disclosed modipafant’s Investigator’s Brochure to 60P under confidentiality. An"/>
 <result pre="microfilarial nematode similar to O. volvulus, Professor Cho-Ngwa connected with" exact="Merck" post="KGaA through BVGH. With a strong interest in fostering"/>
 <result pre="South to address IP barriers and accelerate infectious disease R&amp;amp;D," exact="Merck" post="KGaA shared 5600 compounds (including Hsp90 inhibitors and molecules"/>
 <result pre="pathways) with Professor Cho-Ngwa. Using BVGH FundFinder, BVGH identified the" exact="Wellcome Trust" post="Pathfinder Award—which aims to stimulate partnerships between companies and"/>
 <result pre="a potential funding source for this project. Professor Cho-Ngwa and" exact="Merck" post="KGaA co-applied for the grant and received US$184,000, which"/>
 <result pre="hit-to-lead optimization, and they are co-preparing a second proposal to" exact="Wellcome Trust" post="to support this work. As part of the ongoing"/>
 <result pre="work. As part of the ongoing partnership with Professor Cho-Ngwa," exact="Merck" post="KGaA will contribute expertise from departments such as Corporate"/>
 <result pre="Re:Search network. Acknowledgments We thank our colleagues at 60P Pharmaceuticals;" exact="Eisai" post="Co., Ltd.; Johnson &amp;amp; Johnson; Liverpool School of Tropical"/>
 <result pre="Co., Ltd.; Johnson &amp;amp; Johnson; Liverpool School of Tropical Medicine;" exact="Merck" post="KGaA; MSD; Pfizer; University of Buea; University of California,"/>
 <result pre="of Tropical Medicine; Merck KGaA; MSD; Pfizer; University of Buea;" exact="University of California," post="San Diego; and Walter and Eliza Hall Institute of"/>
 <result pre="Health (BVGH). BVGH currently receives WIPO Re:Search sponsorship funding from" exact="Eisai" post="Co., Ltd.; GlaxoSmithKline; Johnson &amp;amp; Johnson; Merck KGaA; MSD;"/>
 <result pre="sponsorship funding from Eisai Co., Ltd.; GlaxoSmithKline; Johnson &amp;amp; Johnson;" exact="Merck" post="KGaA; MSD; Novartis; Pfizer; and Takeda Pharmaceutical Company, Ltd,"/>
 <result pre="GlaxoSmithKline; Johnson &amp;amp; Johnson; Merck KGaA; MSD; Novartis; Pfizer; and" exact="Takeda Pharmaceutical Company," post="Ltd, and previously received WIPO Re:Search sponsorship funding from"/>
 <result pre="sponsorship funding from 60P Pharmaceuticals. Conflicts of Interest 60P Pharmaceuticals;" exact="Eisai" post="Co., Ltd.; Johnson &amp;amp; Johnson; Merck KGaA; MSD; and"/>
 <result pre="of Interest 60P Pharmaceuticals; Eisai Co., Ltd.; Johnson &amp;amp; Johnson;" exact="Merck" post="KGaA; MSD; and Pfizer reviewed and approved the descriptions"/>
 <result pre="Eisai Co., Ltd.; Johnson &amp;amp; Johnson; Merck KGaA; MSD; and" exact="Pfizer" post="reviewed and approved the descriptions of their WIPO Re:Search"/>
 <result pre="ResearchSydney, Australia2019Available online: https://www.policycuresresearch.org/wp-content/uploads/Y11_G-FINDER_Full_report_Reaching_new_heights.pdf(accessed on 19 March 2019) 12.Health Product" exact="Research and Development" post="Fund: A Proposal for Financing and OperationWorld Health Organization"/>
</results>
